STOCK TITAN

[6-K] BioNTech SE Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Analyzing...
Positive
  • None.
Negative
  • None.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF OCTOBER 2025

COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F Form 40‑F
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7):




DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On October 1, 2025, BioNTech SE (“BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd., hosted its second AI Day, an edition of BioNTech’s “Innovation Series”, providing an overview of BioNTech’s AI strategy and capabilities and the application of AI in BioNTech’s pipeline and internal processes. The presentation is attached hereto as Exhibit 99.1.



SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By:/s/ Ramon Zapata-GomezBy:/s/ Dr. Sierk Poetting
Name: Ramon Zapata-GomezName: Dr. Sierk Poetting
Title: Chief Financial OfficerTitle: Chief Operating Officer
Date: October 1, 2025



EXHIBIT INDEX
ExhibitDescription of Exhibit
99.1
Presentation




BIONTECH

NASDAQ:BNTX

BNTX Rankings

BNTX Latest News

BNTX Latest SEC Filings

BNTX Stock Data

23.71B
89.69M
62.69%
23.12%
2.5%
Biotechnology
Healthcare
Link
Germany
Mainz